S
Similasan
Similasan agreed to pay $3.575 million to settle claims that its homeopathic eye drops were deceptively labeled and advertised.
ClosedUnited States-wideClaim status: Closed on October 15, 2025Payout: VariesNo longer claimable
About this settlement
The case addresses deceptive labeling and advertising of homeopathic eye drops sold by Similasan and retailers.
This settlement resolves claims that Similasan's homeopathic eye drops were deceptively labeled and advertised. Eligible consumers who purchased certain Similasan, CVS, or Walgreens eye drop products during the specified period may submit claims for compensation.
Who qualifies
- Consumers who purchased specified Similasan, CVS, or Walgreens eye drop products.
- Purchases made between September 11, 2017 and February 20, 2025.
Varies
Claim status: Closed on October 15, 2025